News

5 Insightful Analyst Questions From Amgen’s Q2 Earnings Call

Amgen’s second quarter results outpaced Wall Street’s expectations, with management emphasizing strong demand for its ...

AMGN Q2 Deep Dive: Volume Growth, Pipeline Progress, and Guidance Raise Meet Investor Skepticism

Biotech company Amgen (NASDAQ:AMGN) beat Wall Street’s revenue expectations in Q2 CY2025, with sales up 9.4% year on year to ...

Special report: New weight-loss drugs experts say are BETTER than Ozempic - from the 'gym in a jab', to the injection you take just twice a year

More than one in five UK adults tried to access weight-loss medications in the past year alone, according to a survey by the ...
Zacks Investment Research on MSN3d

Novo Nordisk Rises 6% So Far in August: How to Play the Stock

Novo Nordisk NVO faced a significant setback in July after sharply reducing its 2025 outlook for both sales and operating ...

Eli Lilly Vs. Novo Nordisk: Correction Overly Done - GLP-1 Market Leadership/ Robust Pipelines Ahead

Novo Nordisk's (NVO) corrections amid AI market rotation might be an opportunity, due to GLP-1 market leadership & balanced ...

Amgen (AMGN) Receives a Hold from Wells Fargo

Currently, the analyst consensus on Amgen is a Moderate Buy with an average price target of $328.83, a 15.51% upside from current levels. In a report released yesterday, Citi also maintained a Hold ...
Everyday Health6d

New Weight Loss Drugs Aim to Rival Ozempic - Everyday Health

The next generation of diabetes and weight loss drugs could come in pill form, deliver even greater weight loss results, and provide more health benefits.